BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
An Extended time of Self-Reflection: Self-awareness through Journaling - 2Mali and Canadian miner Barrick agree to resolve tax dispute, ending 2-year standoff
- 3One of the best meteor showers of the year peaks at the worst possible time this week
- 4Mummified cheetahs found in Saudi caves shed light on lost populations
- 5The 10 Most Famous Works of art Ever
- SpaceX launches Starlink satellites on its 150th Falcon 9 mission of the year
- Believe Should Unwind? Look at These Scaled down Games
- Thousands of genomes reveal the wild wolf genes in most dogs’ DNA
- Help Your Efficiency: 10 Authoritative Apparatuses to Attempt
- Climbing Mount Everest: An Individual Victory
- Manual for Tracking down the Mysterious Cascades in China
- November Lease Deals for the 2025 Kia EV6 are Too Good to Pass Up
- Witness the elegance of the cosmic butterfly in a remarkable telescope photo
- Data centers in space: Will 2027 really be the year AI goes to orbit?
